Contrasting Zynerba Pharmaceuticals (ZYNE) and The Competition
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Zynerba Pharmaceuticals to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Volatility and Risk
Zynerba Pharmaceuticals has a beta of 5.33, indicating that its share price is 433% more volatile than the S&P 500. Comparatively, Zynerba Pharmaceuticals’ rivals have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.
Valuation & Earnings
This table compares Zynerba Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Zynerba Pharmaceuticals||N/A||-$28.66 million||-2.38|
|Zynerba Pharmaceuticals Competitors||$207.14 million||-$2.51 million||0.26|
Zynerba Pharmaceuticals’ rivals have higher revenue and earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for Zynerba Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Zynerba Pharmaceuticals Competitors||785||2925||6381||144||2.57|
Zynerba Pharmaceuticals currently has a consensus price target of $11.13, suggesting a potential upside of 78.57%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.30%. Given Zynerba Pharmaceuticals’ higher possible upside, research analysts plainly believe Zynerba Pharmaceuticals is more favorable than its rivals.
This table compares Zynerba Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Zynerba Pharmaceuticals Competitors||-3,680.23%||-415.63%||-47.84%|
Insider & Institutional Ownership
34.3% of Zynerba Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.0% of Zynerba Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Zynerba Pharmaceuticals rivals beat Zynerba Pharmaceuticals on 8 of the 12 factors compared.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.